BI-765250
- Generic Name
- BI-765250
A Study to Test How Well Different Doses of BI 765250 Are Tolerated by People With a Skin Disease Called Plaque Psoriasis
- First Posted Date
- 2023-02-15
- Last Posted Date
- 2025-03-07
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 64
- Registration Number
- NCT05728489
- Locations
- 🇧🇬
MBAL Sveta Sofia, Sofia, Bulgaria
🇬🇪ARENSIA Exploratory Medicine LLC, Tbilisi, Georgia
🇲🇩Clinical Republican Hospital "Timofei Mosneaga", Chisinau, Moldova, Republic of
A Study to Test How Well Healthy Men Tolerate BI 765250 When Given as an Infusion Into the Vein or as an Injection Under the Skin
- First Posted Date
- 2021-12-09
- Last Posted Date
- 2025-01-22
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 135
- Registration Number
- NCT05151653
- Locations
- 🇧🇪
SGS Life Science Services - Clinical Research, Edegem, Belgium
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath